1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Delivery System Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gene Delivery System Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Delivery System Market Analysis and Forecast, by Delivery System
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Delivery System, 2017–2031
6.3.1. Viral Gene Delivery
6.3.1.1. Adenovirus Vector
6.3.1.2. Lentivirus Vector
6.3.1.3. Retrovirus Vector
6.3.1.4. Adeno-associated Virus Vector
6.3.1.5. Sendai Virus Vector
6.3.1.6. Herpes Simplex Virus Vector
6.3.1.7. Others
6.3.2. Non-viral Gene Delivery
6.3.2.1. Natural Organic Compounds
6.3.2.2. Physical Methods
6.3.2.3. Chemical Methods
6.3.3. Combined Hybrid Delivery
6.4. Market Attractiveness Analysis, by Delivery System
7. Global Gene Delivery System Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Infectious Diseases
7.3.2. Oncology
7.3.3. Ophthalmology
7.3.4. Urology
7.3.5. Diabetes
7.3.6. CNS
7.3.7. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Gene Delivery System Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Injectable
8.3.3. Inhalation
8.3.4. Transdermal
8.3.5. Ocular
8.3.6. Nasal
8.3.7. Topical
8.4. Market Attractiveness Analysis, by Application
9. Global Gene Delivery System Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Gene Delivery System Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Delivery System, 2017–2031
10.3.1. Viral Gene Delivery
10.3.1.1. Adenovirus Vector
10.3.1.2. Lentivirus Vector
10.3.1.3. Retrovirus Vector
10.3.1.4. Adeno-associated Virus Vector
10.3.1.5. Sendai Virus Vector
10.3.1.6. Herpes Simplex Virus Vector
10.3.1.7. Others
10.3.2. Non-viral Gene Delivery
10.3.2.1. Natural Organic Compounds
10.3.2.2. Physical Methods
10.3.2.3. Chemical Methods
10.3.2.4. Acute Dialysis Products
10.3.3. Combined Hybrid Delivery
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Infectious Diseases
10.4.2. Oncology
10.4.3. Ophthalmology
10.4.4. Urology
10.4.5. Diabetes
10.4.6. CNS
10.4.7. Others
10.5. Market Value Forecast, by Route of Administration, 2017–2031
10.5.1. Oral
10.5.2. Injectable
10.5.3. Inhalation
10.5.4. Transdermal
10.5.5. Ocular
10.5.6. Nasal
10.5.7. Topical
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Delivery System
10.7.2. By Application
10.7.3. By Route of Administration
10.7.4. By Country
11. Europe Gene Delivery System Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Delivery System, 2017–2031
11.3.1. Viral Gene Delivery
11.3.1.1. Adenovirus Vector
11.3.1.2. Lentivirus Vector
11.3.1.3. Retrovirus Vector
11.3.1.4. Adeno-associated Virus Vector
11.3.1.5. Sendai Virus Vector
11.3.1.6. Herpes Simplex Virus Vector
11.3.1.7. Others
11.3.2. Non-viral Gene Delivery
11.3.2.1. Natural Organic Compounds
11.3.2.2. Physical Methods
11.3.2.3. Chemical Methods
11.3.2.4. Acute Dialysis Products
11.3.3. Combined Hybrid Delivery
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Infectious Diseases
11.4.2. Oncology
11.4.3. Ophthalmology
11.4.4. Urology
11.4.5. Diabetes
11.4.6. CNS
11.4.7. Others
11.5. Market Value Forecast, by Route of Administration, 2017–2031
11.5.1. Oral
11.5.2. Injectable
11.5.3. Inhalation
11.5.4. Transdermal
11.5.5. Ocular
11.5.6. Nasal
11.5.7. Topical
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Delivery System
11.7.2. By Application
11.7.3. By Route of Administration
11.7.4. By Country/Sub-region
12. Asia Pacific Gene Delivery System Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Delivery System, 2017–2031
12.3.1. Viral Gene Delivery
12.3.1.1. Adenovirus Vector
12.3.1.2. Lentivirus Vector
12.3.1.3. Retrovirus Vector
12.3.1.4. Adeno-associated Virus Vector
12.3.1.5. Sendai Virus Vector
12.3.1.6. Herpes Simplex Virus Vector
12.3.1.7. Others
12.3.2. Non-viral Gene Delivery
12.3.2.1. Natural Organic Compounds
12.3.2.2. Physical Methods
12.3.2.3. Chemical Methods
12.3.2.4. Acute Dialysis Products
12.3.3. Combined Hybrid Delivery
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Infectious Diseases
12.4.2. Oncology
12.4.3. Ophthalmology
12.4.4. Urology
12.4.5. Diabetes
12.4.6. CNS
12.4.7. Others
12.5. Market Value Forecast, by Route of Administration, 2017–2031
12.5.1. Oral
12.5.2. Injectable
12.5.3. Inhalation
12.5.4. Transdermal
12.5.5. Ocular
12.5.6. Nasal
12.5.7. Topical
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Delivery System
12.7.2. By Application
12.7.3. By Route of Administration
12.7.4. By Country/Sub-region
13. Latin America Gene Delivery System Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Delivery System, 2017–2031
13.3.1. Viral Gene Delivery
13.3.1.1. Adenovirus Vector
13.3.1.2. Lentivirus Vector
13.3.1.3. Retrovirus Vector
13.3.1.4. Adeno-associated Virus Vector
13.3.1.5. Sendai Virus Vector
13.3.1.6. Herpes Simplex Virus Vector
13.3.1.7. Others
13.3.2. Non-viral Gene Delivery
13.3.2.1. Natural Organic Compounds
13.3.2.2. Physical Methods
13.3.2.3. Chemical Methods
13.3.2.4. Acute Dialysis Products
13.3.3. Combined Hybrid Delivery
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Infectious Diseases
13.4.2. Oncology
13.4.3. Ophthalmology
13.4.4. Urology
13.4.5. Diabetes
13.4.6. CNS
13.4.7. Others
13.5. Market Value Forecast, by Route of Administration, 2017–2031
13.5.1. Oral
13.5.2. Injectable
13.5.3. Inhalation
13.5.4. Transdermal
13.5.5. Ocular
13.5.6. Nasal
13.5.7. Topical
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Delivery System
13.7.2. By Application
13.7.3. By Route of Administration
13.7.4. By Country/Sub-region
14. Middle East & Africa Gene Delivery System Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Delivery System, 2017–2031
14.3.1. Viral Gene Delivery
14.3.1.1. Adenovirus Vector
14.3.1.2. Lentivirus Vector
14.3.1.3. Retrovirus Vector
14.3.1.4. Adeno-associated Virus Vector
14.3.1.5. Sendai Virus Vector
14.3.1.6. Herpes Simplex Virus Vector
14.3.1.7. Others
14.3.2. Non-viral Gene Delivery
14.3.2.1. Natural Organic Compounds
14.3.2.2. Physical Methods
14.3.2.3. Chemical Methods
14.3.2.4. Acute Dialysis Products
14.3.3. Combined Hybrid Delivery
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Infectious Diseases
14.4.2. Oncology
14.4.3. Ophthalmology
14.4.4. Urology
14.4.5. Diabetes
14.4.6. CNS
14.4.7. Others
14.5. Market Value Forecast, by Route of Administration, 2017–2031
14.5.1. Oral
14.5.2. Injectable
14.5.3. Inhalation
14.5.4. Transdermal
14.5.5. Ocular
14.5.6. Nasal
14.5.7. Topical
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Delivery System
14.7.2. By Application
14.7.3. By Route of Administration
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Amgen Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Oxford Biomedica PLC
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sibiono GeneTech Co., Ltd.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Shanghai Sunway Biotech Co., Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Bayer AG
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Johnson & Johnson Services, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Human Stem Cells Institute
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
